# ANALYSIS OF NON-SMALL CELL LUNG CARCINOMA ANTIGENS

> **NIH NIH R01** · SCRIPPS RESEARCH INSTITUTE, THE · 1990 · $168,574

## Abstract

The overall aim is to study in depth mechanisms involved in tumor invasion
at the biological and molecular levels and to extend ongoing studies on
monoclonal antibody-directed targeting of chemotherapeutic drugs.  This
involves the development of new and novel targeting agents using monoclonal
antibodies to synthetic peptides selected from the amino acid sequence of a
recognized tumor antigen.  In order to gain a basic understanding at the
molecular level of the significance of tumor antigen structure as it
relates to tumor cell killing we plan to define the antigenic and
functional sites of the 40,000 Mr antigen recognized by the monoclonal
antibody KS1/4.  This antigen is highly relevant for this purpose since it
is:  1) strongly associated with non-small cell lung carcinoma, 2) present
in extremely high quantities on the surface of tumor cells, 3) a highly
efficient target for monoclonal antibody and monoclonal antibody-drug
conjugates directed in vivo killing of adenocarcinoma of the lung cells
when established in athymic mice and 4) the antigen which serves as the
target for the recently initiated clinical trial using monoclonal
antibody-drug conjugates.  The basic underlying theme of this proposal is
to utilize the structure of the p40 antigen to generate reagents that will
clarify the relationship between antigenic determinants in and monoclonal
antibodies that destroy tumor cells.  The complete amino acid sequence will
be determined by a combination of amino acid sequence analysis and
nucleotide sequence analysis of c-DNA.  Selected peptides will be
synthesized and used as immunogens for the production of monoclonal
antibodies.  These monoclonal antibodies will then be tested for their
ability to kill tumor cells in an animal model system.  Such use of
monoclonal antibodies alone, in combination with another and conjugated to
drugs will greatly aid gaining an understanding of the different modalities
of tumor killing as they relate to antigen structure.  Finally, the cloned
gene of the p40 antigen will be inserted into an existing mouse tumor in
order to produce a more realistic model to assess the therapeutic role of
monoclonal antibodies to human tumor antigens in a model system involving
immunologically competent animals.

## Key facts

- **NIH application ID:** 3172582
- **Project number:** 5R01CA034778-08
- **Recipient organization:** SCRIPPS RESEARCH INSTITUTE, THE
- **SAM.gov UEI:** PHZJFZ32NKH4
- **Principal Investigator:** PER A PETERSON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1990
- **Award amount:** $168,574
- **Award type:** 5
- **Project period:** 1983-05-01 → 1991-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3172582

## Citation

> US National Institutes of Health, RePORTER application 3172582, ANALYSIS OF NON-SMALL CELL LUNG CARCINOMA ANTIGENS (5R01CA034778-08). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3172582. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*